Company Filing History:
Years Active: 2009
Title: Ning-Yi Li: Innovator in Cancer Detection and Treatment
Introduction: Ning-Yi Li, based in Taipei, Taiwan, is a notable inventor recognized for his contributions to cancer research. His innovations focus on molecular biology and oncology, addressing critical challenges in the detection and treatment of cancer. With one patent to his name, he stands at the forefront of advancing medical diagnostics.
Latest Patents: Ning-Yi Li holds a significant patent for the cancer-specific gene MH15 (Hn1L), identified as an oncogene. This patent encompasses methods and compositions for detecting and diagnosing cancer by assessing the expression levels of MH15 in biological samples. Additionally, his work provides methods for screening inhibitors and moderators of MH15 expression and activity, alongside compositions containing compounds aimed at inhibiting or moderating MH15, with the goal of cancer treatment in vivo.
Career Highlights: Li is an esteemed employee of Medigen Biotechnology Corporation, where he applies his research and innovative capabilities to develop cutting-edge solutions in the field of biotechnology. His work has the potential to transform cancer diagnostics and therapeutic strategies.
Collaborations: Throughout his career, Ning-Yi Li has worked alongside notable professionals such as Stanley Chang and Hsun-Lang Chang. Their collaborative efforts contribute to enhancing the understanding and management of cancer through innovative research and development.
Conclusion: Ning-Yi Li's contributions to cancer research and his dedication to developing effective therapeutic methods underscore his importance as an inventor in the field of biomedical innovation. His work with the MH15 oncogene not only holds promise for improving diagnostic techniques but also offers new avenues for cancer treatment, highlighting the vital intersection of research, invention, and practical application in medicine.